Novel modified corin molecules having substitute activation sequences and uses thereof

Details for Australian Patent Application No. 2004248192 (hide)

Owner Schering Akitengesellschaft

Inventors Wu, Qingyu

Agent Davies Collison Cave

Pub. Number AU-A-2004248192

PCT Pub. Number WO2004/111225

Priority 60/477,683 11.06.03 US

Filing date 9 June 2004

Wipo publication date 23 December 2004

International Classifications

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 15/57 (2006.01) Mutation or genetic engineering - acting on peptide bonds (3.4)

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2004/111225 Priority application(s): WO2004/111225

21 September 2006 Change of Name(s) of Applicant(s), Section 104

  Schering Akitengesellschaft The name of the applicant has been changed to Schering Aktiengesellschaft

14 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004248203-Method of characterization of surface coating containing metallic flakes and device used therein

2004248187-Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors